A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy ( (ADHERE)

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy ( (ADHERE)
Recruiting
18 years - 99 years
All
Phase 2
10 participants needed
1 Location

Brief description of study

Study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Demyelinating Polyneuropathy
  • Age: 18 years - 99 years
  • Gender: All

Male and Female Age 18 or older Diagnosed with probable or definite CIDP

Updated on 04 Aug 2024. Study ID: 834668

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center